PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

Seock-Ah Im; Binghe Xu; Sung-Bae Kim; Wei-Pang Chung; Yeon hee Park; Min-Hwan Kim; Ling-Ming Tseng; Chi-Feng Chung; Chiun-Sheng Huang; Jee hyun Kim; Joanne wing Yan chiu; Toshinari Yamashita; Wei Li; Caleb Lee; Soichiro Nishijima; Kyohei Hamada; Yuji Nishiyama; Masahiro Sugihara; Javier Cortés; Hiroji Iwata

doi:10.1016/j.annonc.2022.05.064

PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

Seock-Ah Im
, Binghe Xu
, Sung-Bae Kim
, Wei-Pang Chung
, Yeon hee Park
, Min-Hwan Kim
, Ling-Ming Tseng
, Chi-Feng Chung
, Chiun-Sheng Huang
, Jee hyun Kim
, Joanne wing Yan chiu
, Toshinari Yamashita
, Wei Li
, Caleb Lee
, Soichiro Nishijima
, Kyohei Hamada
, Yuji Nishiyama
, Masahiro Sugihara
, Javier Cortés
, Hiroji Iwata

Department of Internal Medicine(NCKUH)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S464-S465
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.05.064
Publication status	Published - 2022 Jul 1

Access to Document

10.1016/j.annonc.2022.05.064

https://linkinghub.elsevier.com/retrieve/pii/S0923753422012625

Cite this

Im, S.-A., Xu, B., Kim, S.-B., Chung, W.-P., Park, Y. H., Kim, M.-H., Tseng, L.-M., Chung, C.-F., Huang, C.-S., Kim, J. H., Yan chiu, J. W., Yamashita, T., Li, W., Lee, C., Nishijima, S., Hamada, K., Nishiyama, Y., Sugihara, M., Cortés, J., & Iwata, H. (2022). PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03. Annals of Oncology, 33, S464-S465. https://doi.org/10.1016/j.annonc.2022.05.064

@article{b20917f1ed224569b58b8914ddef8fa4,

title = "PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03",

author = "Seock-Ah Im and Binghe Xu and Sung-Bae Kim and Wei-Pang Chung and Park, \{Yeon hee\} and Min-Hwan Kim and Ling-Ming Tseng and Chi-Feng Chung and Chiun-Sheng Huang and Kim, \{Jee hyun\} and \{Yan chiu\}, \{Joanne wing\} and Toshinari Yamashita and Wei Li and Caleb Lee and Soichiro Nishijima and Kyohei Hamada and Yuji Nishiyama and Masahiro Sugihara and Javier Cort{\'e}s and Hiroji Iwata",

year = "2022",

month = jul,

day = "1",

doi = "10.1016/j.annonc.2022.05.064",

language = "English",

volume = "33",

pages = "S464--S465",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

}

Im, S-A, Xu, B, Kim, S-B, Chung, W-P, Park, YH, Kim, M-H, Tseng, L-M, Chung, C-F, Huang, C-S, Kim, JH, Yan chiu, JW, Yamashita, T, Li, W, Lee, C, Nishijima, S, Hamada, K, Nishiyama, Y, Sugihara, M, Cortés, J & Iwata, H 2022, 'PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03', Annals of Oncology, vol. 33, pp. S464-S465. https://doi.org/10.1016/j.annonc.2022.05.064

TY - JOUR

T1 - PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

AU - Im, Seock-Ah

AU - Xu, Binghe

AU - Kim, Sung-Bae

AU - Chung, Wei-Pang

AU - Park, Yeon hee

AU - Kim, Min-Hwan

AU - Tseng, Ling-Ming

AU - Chung, Chi-Feng

AU - Huang, Chiun-Sheng

AU - Kim, Jee hyun

AU - Yan chiu, Joanne wing

AU - Yamashita, Toshinari

AU - Li, Wei

AU - Lee, Caleb

AU - Nishijima, Soichiro

AU - Hamada, Kyohei

AU - Nishiyama, Yuji

AU - Sugihara, Masahiro

AU - Cortés, Javier

AU - Iwata, Hiroji

PY - 2022/7/1

Y1 - 2022/7/1

U2 - 10.1016/j.annonc.2022.05.064

DO - 10.1016/j.annonc.2022.05.064

M3 - Article

SN - 0923-7534

VL - 33

SP - S464-S465

JO - Annals of Oncology

JF - Annals of Oncology

ER -